HAVCR2 and lung cancer: An increase in TIM-3+ circulating NKs has been reported in lung cancer, associated with immune suppressive TME, NK killing activity inhibition, and the more aggressive disease form, suggesting that it could be a possible therapeutic target in NSCLC (84).